May 24 (Reuters) - Resverlogix Corp RVX.TO
* Potential of Apabetalone for treatment of high-risk
diabetes and CKD is being explored in co's phase 3 Betonmace
clinical study
* Says no increase in infections was reported in phase 2
trials
Source text for Eikon: ID:nPreyTYCPa
Further company coverage: RVX.TO